...
首页> 外文期刊>Journal of Clinical Microbiology >Cellular Profiles of Bronchoalveolar Lavage Fluid and Their Prognostic Significance for Non-HIV-Infected Patients with Pneumocystis jirovecii Pneumonia
【24h】

Cellular Profiles of Bronchoalveolar Lavage Fluid and Their Prognostic Significance for Non-HIV-Infected Patients with Pneumocystis jirovecii Pneumonia

机译:支气管肺泡灌洗液的细胞谱及其对非HIV感染的布氏肺孢子虫肺炎患者的预后意义

获取原文
           

摘要

The usefulness of bronchoalveolar lavage (BAL) fluid cellular analysis in non-human immunodeficiency virus (HIV)-infected patients with Pneumocystis jirovecii pneumonia (PCP) has not been adequately evaluated. The objective of this study was to analyze the cellular profiles of BAL fluid and to evaluate their prognostic significance in non-HIV-infected patients with PCP. A 7-year retrospective cohort study of 166 non-HIV-infected adult patients with PCP who underwent BAL was performed in a tertiary care hospital. The median total BAL fluid white blood cell count was 180/μl (interquartile range, 80 to 330) and was unaffected by the severity of PCP. The median percentages of BAL fluid neutrophils, lymphocytes, and alveolar macrophages were 13.1%, 31.7%, and 30.2%, respectively. The median percentage of BAL fluid neutrophils was significantly higher in severe than in mild-to-moderate PCP (20.4% versus 6.0%, P < 0.001), as was the absolute neutrophil count (24/μl versus 13/μl, P = 0.001). The percentage of BAL fluid neutrophils was an independent predictor of 30-day (adjusted odds ratio [aOR], 1.02; 95% confidence interval [CI], 1.01 to 1.03) and 60-day (aOR, 1.02; 95% CI, 1.01 to 1.04) mortalities. The 30-day and 60-day mortalities increased at rates of 15% (P = 0.006) and 21% (P < 0.001) per 10% increment of BAL fluid neutrophil levels, respectively. The degree of BAL fluid pleocytosis was relatively low without regard to the severity of PCP. The percentage of BAL fluid neutrophils can be used as a prognostic marker in non-HIV-infected patients with PCP.
机译:尚未充分评估支气管肺泡灌洗(BAL)液细胞分析在非人类免疫缺陷病毒(HIV)感染的肺炎支原体肺炎(PCP)患者中的有用性。这项研究的目的是分析BAL液的细胞谱,并评估其在非HIV感染的PCP患者中的预后意义。在一家三级护理医院进行了一项为期7年的回顾性队列研究,对166例接受BAL的未感染HIV的PCP成人患者进行了研究。中位总BAL液白细胞计数中位数为180 /μl(四分位间距为80至330),不受PCP严重程度的影响。 BAL液体中性粒细胞,淋巴细胞和肺泡巨噬细胞的中位百分比分别为13.1%,31.7%和30.2%。重度BAL液体中性粒细胞的中位数百分比显着高于轻度至中度PCP(20.4%对6.0%, P <0.001),绝对中性粒细胞计数(24 /μl对13 /μl, P = 0.001)。 BAL液体中性粒细胞的百分比是30天(调整后的优势比[aOR],1.02; 95%置信区间[CI],1.01至1.03)和60天(aOR,1.02; 95%CI,1.01)的独立预测因子至1.04)的死亡率。每增加10%的BAL液体中性粒细胞,死亡率30天和60天的死亡率分别增加15%( P = 0.006)和21%( P <0.001)级别。不管PCP的严重程度如何,BAL液体的胞吞作用程度都相对较低。在非HIV感染的PCP患者中,BAL中性粒细胞的百分比可以用作预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号